Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Sarcomas are a heterogeneous group of rare malignancies that arise from mesenchymal cells and can occur anywhere in the body. Herein, the focus will be on one subtype of sarcoma that arises from adipocytic tissue, liposarcoma. Specifically, the review will focus on one type of liposarcoma, myxoid liposarcoma. Given the rarity of this tumor, it is imperative that these patients are treated at a sarcoma center, where a multidisciplinary approach incorporates all the modalities available including clinical trials. As the understanding of the biology of myxoid liposarcomas progresses, more targeted therapies are being developed that will lead to better tolerated treatments and improved survival for patients. In this review, we will be discussing the pathophysiology, clinical presentation, diagnostic workup, and available treatment options including surgery, radiation, chemotherapy, and clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hui JY. Epidemiology and etiology of sarcomas. Surg Clin North Am. 2016;96(5):901–14. https://doi.org/10.1016/j.suc.2016.05.005.

    Article  PubMed  Google Scholar 

  2. Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2(1):14. https://doi.org/10.1186/2045-3329-2-14.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.

    Article  Google Scholar 

  4. Guan Z, Yu X, Wang H, Wang H, Zhang J, Li G, et al. Advances in the targeted therapy of liposarcoma. Onco Targets Ther. 2015;8:125–36. https://doi.org/10.2147/OTT.S72722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lee ATJ, Thway K, Huang PH, Jones RL. Clinical and molecular spectrum of liposarcoma. J Clin Oncol. 2018;36(2):151–9. https://doi.org/10.1200/JCO.2017.74.9598.

    Article  CAS  PubMed  Google Scholar 

  6. Crago AM, Dickson MA. Liposarcoma: multimodality management and future targeted therapies. Surg Oncol Clin N Am. 2016;25(4):761–73. https://doi.org/10.1016/j.soc.2016.05.007.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2007;109(12):2522–31. https://doi.org/10.1002/cncr.22720.

    Article  PubMed  Google Scholar 

  8. Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres K, Colombo C, et al. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013;119(10):1868–77. https://doi.org/10.1002/cncr.27847.

    Article  CAS  PubMed  Google Scholar 

  9. ten Heuvel SE, Hoekstra HJ, van Ginkel RJ, Bastiaannet E, Suurmeijer AJ. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol. 2007;14(1):222–9. https://doi.org/10.1245/s10434-006-9043-7.

    Article  PubMed  Google Scholar 

  10. Tateishi U, Hasegawa T, Beppu Y, Kawai A, Satake M, Moriyama N. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol. 2004;182(3):725–31. https://doi.org/10.2214/ajr.182.3.1820725.

    Article  PubMed  Google Scholar 

  11. Lowenthal D, Zeile M, Niederhagen M, Fehlberg S, Schnapauff D, Pink D, et al. Differentiation of myxoid liposarcoma by magnetic resonance imaging: a histopathologic correlation. Acta Radiol. 2014;55(8):952–60. https://doi.org/10.1177/0284185113508114.

    Article  CAS  PubMed  Google Scholar 

  12. Pohlig F, Kirchhoff C, Lenze U, Schauwecker J, Burgkart R, Rechl H, et al. Percutaneous core needle biopsy versus open biopsy in diagnostics of bone and soft tissue sarcoma: a retrospective study. Eur J Med Res. 2012;17:29. https://doi.org/10.1186/2047-783X-17-29.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Skrzynski MC, Biermann JS, Montag A, Simon MA. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg Am. 1996;78(5):644–9.

    Article  CAS  Google Scholar 

  14. Ray-Coquard I, Ranchere-Vince D, Thiesse P, Ghesquieres H, Biron P, Sunyach MP, et al. Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. Eur J Cancer. 2003;39(14):2021–5.

    Article  CAS  Google Scholar 

  15. Strauss DC, Qureshi YA, Hayes AJ, Thway K, Fisher C, Thomas JM. The role of core needle biopsy in the diagnosis of suspected soft tissue tumours. J Surg Oncol. 2010;102(5):523–9. https://doi.org/10.1002/jso.21600.

    Article  CAS  PubMed  Google Scholar 

  16. Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol. 1997;4(5):425–31.

    Article  CAS  Google Scholar 

  17. Schmidt H, Bartel F, Kappler M, Wurl P, Lange H, Bache M, et al. Gains of 13q are correlated with a poor prognosis in liposarcoma. Mod Pathol. 2005;18(5):638–44. https://doi.org/10.1038/modpathol.3800326.

    Article  CAS  PubMed  Google Scholar 

  18. Suzuki K, Matsui Y, Endo K, Kubo T, Hasegawa T, Kimura T, et al. Myxoid liposarcoma with EWS-CHOP type 1 fusion gene. Anticancer Res. 2010;30(11):4679–83.

    CAS  PubMed  Google Scholar 

  19. Powers MP, Wang WL, Hernandez VS, Patel KS, Lev DC, Lazar AJ, et al. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Mod Pathol. 2010;23(10):1307–15. https://doi.org/10.1038/modpathol.2010.118.

    Article  CAS  PubMed  Google Scholar 

  20. Bode-Lesniewska B, Frigerio S, Exner U, Abdou MT, Moch H, Zimmermann DR. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion. Genes Chromosomes Cancer. 2007;46(11):961–71. https://doi.org/10.1002/gcc.20478.

    Article  CAS  PubMed  Google Scholar 

  21. Moreau LC, Turcotte R, Ferguson P, Wunder J, Clarkson P, Masri B, et al. Myxoid/round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol. 2012;19(4):1081–8. https://doi.org/10.1245/s10434-011-2127-z.

    Article  PubMed  Google Scholar 

  22. Chung PW, Deheshi BM, Ferguson PC, Wunder JS, Griffin AM, Catton CN, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009;115(14):3254–61. https://doi.org/10.1002/cncr.24375.

    Article  PubMed  Google Scholar 

  23. Morton DL, Eilber FR, Townsend CM Jr, Grant TT, Mirra J, Weisenburger TH. Limb salvage from a multidisciplinary treatment approach for skeletal and soft tissue sarcomas of the extremity. Ann Surg. 1976;184(3):268–78.

    Article  CAS  Google Scholar 

  24. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.

    Article  CAS  Google Scholar 

  25. Trovik CS, Bauer HC, Alvegard TA, Anderson H, Blomqvist C, Berlin O, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer. 2000;36(6):710–6.

    Article  CAS  Google Scholar 

  26. Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol. 2005;23(1):96–104. https://doi.org/10.1200/JCO.2005.04.160.

    Article  CAS  PubMed  Google Scholar 

  27. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235(3):424–34.

    Article  Google Scholar 

  28. Zagars GK, Goswitz MS, Pollack A. Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1996;36(2):311–9.

    Article  CAS  Google Scholar 

  29. Pitson G, Robinson P, Wilke D, Kandel RA, White L, Griffin AM, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys. 2004;60(2):522–6. https://doi.org/10.1016/j.ijrobp.2004.03.009.

    Article  PubMed  Google Scholar 

  30. O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41. https://doi.org/10.1016/S0140-6736(02)09292-9.

    Article  PubMed  Google Scholar 

  31. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol. 1996;61(2):90–9. https://doi.org/10.1002/(SICI)1096-9098(199602)61:2<90::AID-JSO2>3.0.CO;2-M.

    Article  CAS  PubMed  Google Scholar 

  32. Eilber FC, Brennan MF, Eilber FR, Dry SM, Singer S, Kattan MW. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer. 2004;101(10):2270–5. https://doi.org/10.1002/cncr.20570.

    Article  PubMed  Google Scholar 

  33. Pasquali S, Colombo C, Bottelli S, Verderio P, Broto JM, Lopez-Pousa A, et al. The sarculator stratified prognosis of patients with high-risk soft tissue sarcomas (STS) of extremities and trunk wall treated with perioperative chemotherapy in a randomised controlled trial (RCT). J Clin Oncol. 2017;35(15_suppl):11016. https://doi.org/10.1200/JCO.2017.35.15_suppl.11016.

    Article  Google Scholar 

  34. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47. https://doi.org/10.1200/JCO.2001.19.5.1238.

    Article  CAS  PubMed  Google Scholar 

  35. Schenone AD, Luo J, Montgomery L, Morgensztern D, Adkins DR, Van Tine BA. Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. Cancer Med. 2014;3(3):603–12. https://doi.org/10.1002/cam4.209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850–6. https://doi.org/10.1200/JCO.2011.37.7218.

    Article  CAS  PubMed  Google Scholar 

  37. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22. https://doi.org/10.1016/S1470-2045(17)30334-0.

    Article  CAS  PubMed  Google Scholar 

  38. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75. https://doi.org/10.1200/JCO.1993.11.7.1269.

    Article  CAS  PubMed  Google Scholar 

  39. Blum RH, Edmonson J, Ryan L, Pelletier L. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 1993;31(Suppl 2):S238–40.

    PubMed  Google Scholar 

  40. •• Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–97. https://doi.org/10.1016/S0140-6736(16)30587-6. Clinical trial that established new standard of care with adriamycin and olaratumab as the trial showed a vastly superior median overall survival with dual combination versus adriamycin alone.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8(2):449–57. https://doi.org/10.1158/1535-7163.MCT-08-0848.

    Article  CAS  PubMed  Google Scholar 

  42. • Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic Liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786–93. https://doi.org/10.1200/JCO.2015.62.4734. Trabectedin was FDA-approved as second-line therapy following this clinical trial revealing decreased risk of progression compared to dacarbazine.

    Article  CAS  PubMed  Google Scholar 

  43. Barone A, Chi DC, Theoret MR, Chen H, He K, Kufrin D, et al. FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen. Clin Cancer Res. 2017;23(24):7448–53. https://doi.org/10.1158/1078-0432.CCR-17-0898.

    Article  CAS  PubMed  Google Scholar 

  44. Koliou P, Karavasilis V, Theochari M, Pollack SM, Jones RL, Thway K. Advances in the treatment of soft tissue sarcoma: focus on eribulin. Cancer Manag Res. 2018;10:207–16. https://doi.org/10.2147/CMAR.S143019.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Singhi EK, Moore DC, Muslimani A. Metastatic soft tissue sarcomas: a review of treatment and new pharmacotherapies. P T. 2018;43(7):410–29.

    PubMed  PubMed Central  Google Scholar 

  46. • Demetri GD, Schoffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017;35(30):3433–9. https://doi.org/10.1200/JCO.2016.71.6605. Eribulin was FDA-approved for second-line treatment following this trial showing an improvement in overall survivial as well as progression-free survival compared to dacarbazine.

    Article  CAS  PubMed  Google Scholar 

  47. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. https://doi.org/10.1016/S0140-6736(12)60651-5.

    Article  CAS  PubMed  Google Scholar 

  48. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32. https://doi.org/10.1200/JCO.2008.21.3223.

    Article  CAS  PubMed  Google Scholar 

  49. Agulnik M, Mohindra NA, Milhem MM, Attia S, Robinson SI, Rademaker A, et al. A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. J Clin Oncol, 2018 ASCO Annual Meeting. 2018;36((suppl; abstr 11550)).

  50. Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011;129(8):1963–9. https://doi.org/10.1002/ijc.25843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C, et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest. 2012;122(3):886–98. https://doi.org/10.1172/JCI60015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Takeuchi A, Yamamoto N, Shirai T, Hayashi K, Miwa S, Munesue S, et al. Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. BMC Cancer. 2016;16:442. https://doi.org/10.1186/s12885-016-2524-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A. 1997;94(1):237–41.

    Article  CAS  Google Scholar 

  54. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999;96(7):3951–6.

    Article  CAS  Google Scholar 

  55. Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012;118(21):5403–13. https://doi.org/10.1002/cncr.27526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Smith SM, Iwenofu OH. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis. Chin Clin Oncol. 2018;7(4):44. https://doi.org/10.21037/cco.2018.08.11.

    Article  PubMed  Google Scholar 

  57. Shurell E, Vergara-Lluri ME, Li Y, Crompton JG, Singh A, Bernthal N, et al. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget. 2016;7(45):72860–7. https://doi.org/10.18632/oncotarget.12096.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012;118(18):4564–70. https://doi.org/10.1002/cncr.27446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Svec D, Dolatabadi S, Thomsen C, Cordes N, Shannon M, Fitzpatrick P, et al. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses. Lab Investig. 2018;98(7):957–67. https://doi.org/10.1038/s41374-018-0046-3.

    Article  CAS  PubMed  Google Scholar 

  60. Tornin J, Hermida-Prado F, Padda RS, Gonzalez MV, Alvarez-Fernandez C, Rey V, et al. FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway. Neoplasia. 2018;20(1):44–56. https://doi.org/10.1016/j.neo.2017.11.004.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, Box 8076 660 S. Euclid Avenue, St. Louis, MO, 63110, USA

    Sarah Abaricia FNP-C, MSN, BSN, RN & Angela C. Hirbe MD, PhD

  2. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA

    Angela C. Hirbe MD, PhD

Authors
  1. Sarah Abaricia FNP-C, MSN, BSN, RN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela C. Hirbe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela C. Hirbe MD, PhD.

Ethics declarations

Conflict of Interest

Sarah Abaricia and Angela C. Hirbe declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abaricia, S., Hirbe, A.C. Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters. Curr. Treat. Options in Oncol. 19, 64 (2018). https://doi.org/10.1007/s11864-018-0590-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-018-0590-5

Keywords

Search

Navigation